



Joint Statement of the European Association of Hospital Pharmacists (EAHP) and the European Association of Nuclear Medicine (EANM)

on the availability of radiopharmaceuticals in the context of the revision of the general pharmaceutical legislation

15 December 2022

Continuing to meet the needs of patients across Europe should, in the opinion of the European Association of Hospital Pharmacists (EAHP) and the European Association of Nuclear Medicine (EANM), be one of the guiding principles for the revision of the general pharmaceutical legislation. Consequently, both associations have joined forces and issued today a **Joint Statement on the availability of radiopharmaceuticals in the context of the revision of the general pharmaceutical legislation** ^[1].

The Joint Statement touches on the need for a flexible regulatory framework for low volume products and enhancing the security of the supply of medicines and addressing shortages. The following calls to action are included:

- Due to the difference between commercial and non-commercial preparations of radiopharmaceuticals, EAHP and EANM are calling for a specific approach to the regulation of small-scale preparation of radiopharmaceuticals.
- To further improve patient care, EAHP and EANM encourage (health) authorities to invest in in-house production services, including compounding services and the preparation of radiopharmaceuticals, and the provision of training tailored to specific preparations, including the expansion of training opportunities. With respect to

radiopharmaceuticals, in-depth knowledge of radiochemistry, radiation safety automated procedures and radiation measurement technology are of particular importance.

- The review of the Pharmaceutical Legislation should consider that, within hospital pharmacies and radiopharmacies, the demand for marketing authorisation should be strictly limited to starting materials and radionuclide precursors used in kit procedures and not for starting materials and radionuclide precursors if used in complex radiopharmaceutical preparations.
- EAHP and EANM call for improved information exchange between authorities and supply chain actors and the relay of information to the end-users. For combatting medicine and radionuclide shortages, best practice sharing is essential, and implementation support for shortage management strategies needs to be provided in the interest of patient safety.

ENDS

For further information contact [info\[at\]eahp\[dot\]eu](mailto:info@eahp.eu) ^[2] | 0032 2 669 2513

1. The European Association of Hospital Pharmacists (EAHP) is a not-for-profit organisation that defends the interests of more than 25.000 European hospital pharmacists from its 36 full and associate member organisations. EAHP works to develop knowledge on hospital pharmacy to ease the improvement of care and outcomes for patients in the hospital setting. The Association achieves this through science, practice, research, education, as well as sharing best-practice and responsibility with other healthcare professionals. More information about EAHP is available [HERE](#) ^[3].

2. Read the Joint Statement of EAHP and EANM on the availability of radiopharmaceuticals in the context of the revision of the general pharmaceutical legislation [HERE](#) ^[1]

15 December 2022

Links

[\[1\]](#)

https://www.eahp.eu/sites/default/files/eahp_eanm_joint_statement_on_the_availability_of_radiopharmaceuticals_in.pdf
[2] <https://www.eahp.eu/contact/info/eahp/eu> [3] <https://www.eahp.eu/about-us/who-we-are>